Adipogenic Adenoviruses as a Biomarker for Disease

Abstract

A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject.

What is claimed is: 
     
         1 . A method of increasing immunity to an adipogenic adenovirus-related cancer in a subject, said method comprising the steps of:
 administering a vaccine composition including a pharmaceutically effective dose of an active ingredient selected from the group consisting of a killed adenovirus type 36, an inactivated adenovirus type 36, a protein or peptide sequence encoding an adenovirus type 36 coat protein or fragment thereof, and an adenovirus type 36 E1A protein, to the subject; and   stimulating the production of adipogenic adenovirus neutralizing antibodies in the subject such that the adipogenic adenovirus neutralizing antibodies increase immunity to the adipogenic adenovirus-related cancer in the subject.   
     
     
         2 . The method of  claim 1 , wherein the vaccine composition in said administering step is administered one or more of intranasally, orally, intravenously, intramuscularly, subcutaneously, and peritoneally. 
     
     
         3 . The method of  claim 1 , wherein the subject is a human. 
     
     
         4 . The method of  claim 1 , wherein the subject is a non-human animal. 
     
     
         5 . The method of  claim 1 , wherein the administration of the vaccine composition is a primary vaccination. 
     
     
         6 . The method of  claim 5 , further comprising the step of administering at least one booster vaccination after the primary vaccination to maintain protective immunity against adipogenic adenovirus in the vaccinated subject. 
     
     
         7 . The method of  claim 1 , wherein the active ingredient has a concentration in the range of about 1 ng/ml to about 1 mg/ml. 
     
     
         8 . The method of  claim 1 , wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml and wherein the active ingredient is inactivated adipogenic adenovirus in an amount in the range of 1 ng/ml to about 1 mg/ml. 
     
     
         9 . The method of  claim 1 , wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml and wherein the active ingredient is an adenovirus type 36 coat protein or fragment thereof in an amount in the range of about 1 ng/ml to about 1 mg/ml. 
     
     
         10 . The method of  claim 9 , wherein the adenovirus type 36 coat protein fragment is a peptide having a length of about 6 amino acids to about 30 amino acids. 
     
     
         11 . The method of  claim 9 , wherein the adenovirus type 36 coat protein is an adenovirus type 36 fiber protein or an adenovirus type 36 fiber protein fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, and SEQ ID No. 7. 
     
     
         12 . The method of  claim 1 , wherein the adipogenic adenovirus is adenovirus type 36. 
     
     
         13 . The method of  claim 1 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, uterine cancer, ovarian cancer, colon cancer, kinder cancer, pancreatic cancer, and lung cancer. 
     
     
         14 . The method of  claim 1 , wherein the cancer is breast cancer. 
     
     
         15 . The method of  claim 1 , wherein the cancer is prostate cancer. 
     
     
         16 . The method of  claim 1 , wherein cancer cells in the subject overexpress fatty acid synthetase (FAS) compared to non-cancer cells from the patient. 
     
     
         17 . The method of  claim 1 , further comprising screening the subject for the presence of an adipogenic adenovirus prior to the administering. 
     
     
         18 . The method of  claim 1 , further comprising screening the subject for the presence of an adipogenic adenovirus after the administering. 
     
     
         19 . The method of  claim 1 , wherein the subject has cancer.